TCL Archive Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months September 27, 2013
TCL Archive The Line Item for Cancer Centers and SPOREs to Remain Flat, Near $598 Million for the 2013 Fiscal Year April 20, 2012
TCL Archive In Brief: Gene Therapy Pioneer Michael Blaese To Leave NIH For Biotechnology Firm January 16, 1998
